. 2015 Jan 21;6(8):5597–5614. doi: 10.18632/oncotarget.3343

Table 5. Up- and down-regulated genes in DLBCL patients with CXCR4⁺ and CXCR4⁻ expression and an IPI≤2 (false discovery rate threshold: .01; P value cutoff: .000058; fold change cutoff: 1.57).

	CXCR4⁺ vs. CXCR4⁻ DLBCL with an IPI ≤2
	Upregulated	Downregulated
Signaling, ion channels		GIMAP2
Cytokine, chemokine		CXCL12
Immune responses, inflammation		SIRPG, TRBC1, LAT, FYB, FYN, LCP2, GVIN1, HLA-DQA1/HLA-DQA2, HLA-DRB1/HLA-DRB4,
DNA recombination, mitotic regulation	AICDA, HELLS, ZWINT
Transcription regulation	CDCA7, AFF3	BCL11B, TXNIP
mRNA editing, translation		ADARB1
Metabolism	FAM72A
Transport, protein modification, folding, chaperone, degradation	AP1S3	SPNS1, APOC1, RTN1
Cell adhesion, cytoskeleton, collagen, extracelluar matrix
Differentiation, development		ITM2A, SLAMF8
Apoptosis, autophage	RASSF6, PEG10	MAF, RASSF4
IncRNA genes, unknown function	C13orf18, FAM129C, RNF183, KLHL23, DPY19L2P2

Table 5. Up- and down-regulated genes in DLBCL patients with CXCR4+ and CXCR4− expression and an IPI≤2 (false discovery rate threshold: .01; P value cutoff: .000058; fold change cutoff: 1.57).